UCLA scientists engineer ready-to-use cancer-fighting T cells for solid tumors
What it is about
Who published it, and when
How it spread - 21 original reports
Tue, 8 September 2026
1 report- newswise.com22:55first to report
UCLA researchers have developed a way to mass-produce cancer-fighting T cells from blood stem cells found in cord blood, engineered to target a protein found in many solid tumors — creating uniform batches instead of custom treatments for each patient.
Fri, 11 September 2026
1 report- miragenews.com20:30
Pediatric oncology researcher Barbara Savoldo, MD, PhD, works to improve treatment options for young patients battling blood cancers, neuroblastoma
Wed, 23 September 2026
1 report- South China Morning Post00:45
In June, Chinese regulators approved the world’s first CAR-T cell therapy for solid tumour cancers, developed by a drug company based in Shanghai. One month later, at a hospital in the city, a New Zealander with advanced cancer of the stomach and small intestine became the first international patient to receive the breakthrough treatment. Chimeric antigen receptor T-cell therapy, to give it its full name, is a cutting-edge treatment that, until then, had only been approved to treat blood...
Thu, 24 September 2026
1 report- miragenews.com20:00
Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR-T cell-associated
Tue, 29 September 2026
1 report- uconn.edu07:20
New program brings potentially lifesaving treatment for certain blood cancers closer to patients in Connecticut and the region
Thu, 1 October 2026
1 report- manilatimes.net11:19
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials
Fri, 2 October 2026
1 report- unc.edu15:15
Grant recipient Eric Bachelder is designing therapies to treat brain cancer and multiple sclerosis by activating the immune system locally.
Thu, 8 October 2026
2 reports- miragenews.com10:30
Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in
- Times of India11:30
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering reduced chemotherapy requirements and lower side effects. Future studies are anticipated to investigate...
Sat, 10 October 2026
1 report- Il Fatto Quotidiano (Italy)12:17
Ogni leucemia può avere caratteristiche diverse e rispondere in modo differente ai trattamenti. Individuare queste specificità è la sfida al centro di due studi dell’Università di Parma, che esplorano le prospettive della medicina funzionale di precisione nelle leucemie linfoblastiche acute a cellule T (Lal-T). La ricerca punta a costruire un profilo della malattia per ciascun […] L'articolo Una “carta d’identità” della leucemia per trovare le cure su misura: dall’Università di Parma due studi...
Mon, 12 October 2026
1 report- newswise.com22:15
An experimental nanoparticle developed by Cedars-Sinai Health Sciences University investigators, which delivers cancer treatment directly to tumors in the brain, has been selected for evaluation by the Nanotechnology Characterization Laboratory (NCL).
Wed, 14 October 2026
1 report- observer.ug13:29
A new technology that destroys cancerous tumours using focused sound waves could eventually offer another treatment choice, including for selected patients in Uganda. The technology, known as histotripsy, can destroy targeted tumour tissue without surgical incisions, radiation or the heat used in some other treatments. It has already received authorization in the United States for […]
Sat, 17 October 2026
1 report- South China Morning Post08:00
For patients with advanced, metastatic cancer that has progressed despite systemic therapy, options remain critically limited. Now, Chinese scientists are pointing to an unconventional therapeutic agent – the element iron. This idea originated in industrial waste water treatment: iron can react with hydrogen peroxide to generate hydroxyl radicals, which degrade various organic and toxic molecules in waste water. Chinese scientists wanted to treat malignant tumours the way they treat waste...
Wed, 21 October 2026
2 reports- miragenews.com12:45
One year after a single treatment, two-thirds of patients who needed walking aids completed a walking test without assistanceNew research led by the
- Telegram.hr (Croatia)13:09
Rezultati ispitivanja imunoterapijskog lijeka pridonijeli su njegovu ubrzanom odobrenju u SAD-u
Fri, 23 October 2026
2 reports- prnewswire.com13:15
/PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease...
- thehoya.com16:08
Editor’s Note: This article is part of a four-part series spotlighting the research labs supported by Georgetown’s BellRinger, an annual fundraiser for cancer research. A cancer research lab at…
Mon, 26 October 2026
2 reports- Le Monde (France)10:15
Dans les formes avancées de cette maladie très agressive, combiner une immunothérapie innovante à une immunothérapie classique, sans attendre la rechute, réduit le risque de décès de 58 %.
- El Mundo (Spain)15:41
Un nuevo fármaco resulta eficaz para reducir la recurrencia del cáncer de endometrio y la mortalidad por esta enfermedad, según revela un importante estudio internacional publicado en 'The Lancet' Leer
Tue, 27 October 2026
2 reports- newswise.com14:50
Dongfang Liu, professor and scientific director of Cellular Imaging and Histology Core, a faculty member in Center for Immunity and Inflammation and Department of Pathology, Immunology and Laboratory Medicine at Rutgers New Jersey Medical School, has discovered a potential way to make drug-resistant liver cancer cells easier for the immune system to spot and destroy. Liu — also an adjacent member of the NJMS-Center for Cell Signaling and a member of the Cancer Metabolism and Immunolo
- medscape.com15:30
A phase 1/2 study evaluates a CAR T-cell therapy engineered to switch off PD-1 and TIGIT in patients with relapsed or refractory large B-cell lymphoma.